Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).
Marchetti C, Ferrandina G, Cormio G, Gambino A, Cecere S, Lorusso D, De Giorgi U, Bogliolo S, Fagotti A, Mammoliti S, Narducci F, Bergamini A, Scollo P, Biglia N, Breda E, Tamberi S, Marinaccio M, Angioli R, Salerno L, Eusebi MC, Loizzi V, Scambia G, Panici PB. Marchetti C, et al. Among authors: cecere s. Gynecol Oncol. 2016 Dec;143(3):532-538. doi: 10.1016/j.ygyno.2016.09.025. Epub 2016 Oct 5. Gynecol Oncol. 2016. PMID: 27717490
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S. Esposito F, et al. Among authors: cecere sc. Oncology. 2014;86(5-6):351-8. doi: 10.1159/000358730. Epub 2014 Jun 12. Oncology. 2014. PMID: 24942520
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pignata S, et al. Among authors: cecere sc. Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14. Lancet Oncol. 2015. PMID: 25882986 Free article. Clinical Trial.
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.
Mangili G, Ottolina J, Cormio G, Loizzi V, De Iaco P, Pellegrini DA, Candiani M, Giorda G, Scarfone G, Cecere SC, Frigerio L, Gadducci A, Marchetti C, Ferrandina G. Mangili G, et al. Among authors: cecere sc. Gynecol Oncol. 2016 Nov;143(2):276-280. doi: 10.1016/j.ygyno.2016.08.316. Epub 2016 Sep 3. Gynecol Oncol. 2016. PMID: 27597380
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Daniele G, Lorusso D, Scambia G, Cecere SC, Nicoletto MO, Breda E, Colombo N, Artioli G, Cannella L, Lo Re G, Raspagliesi F, Maltese G, Salutari V, Ferrandina G, Greggi S, Baldoni A, Bergamini A, Piccirillo MC, Tognon G, Floriani I, Signoriello S, Perrone F, Pignata S. Daniele G, et al. Among authors: cecere sc. Gynecol Oncol. 2017 Feb;144(2):256-259. doi: 10.1016/j.ygyno.2016.12.011. Epub 2016 Dec 16. Gynecol Oncol. 2017. PMID: 27993479 Clinical Trial.
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Di Napoli M, Della Pepa C, Arenare L, Scambia G, Lorusso D, Raspagliesi F, Ferrandina G, Salutari V, Sorio R, Mosconi AM, Mangili G, Borgato L, Lepori S, Salvino A, Pignata S, Cecere SC. Di Napoli M, et al. Among authors: cecere sc. Support Care Cancer. 2017 Jun;25(6):1743-1748. doi: 10.1007/s00520-016-3547-x. Epub 2017 Jan 19. Support Care Cancer. 2017. PMID: 28101677
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F. Pignata S, et al. Among authors: cecere sc. J Clin Oncol. 2017 Oct 10;35(29):3347-3353. doi: 10.1200/JCO.2017.73.4293. Epub 2017 Aug 21. J Clin Oncol. 2017. PMID: 28825853 Clinical Trial.
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC, Scambia G, Bologna A, Signoriello S, Vergote I, Baumann K, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Gallo C, Pignata S, Perrone F. Piccirillo MC, et al. Among authors: cecere sc. Ann Oncol. 2018 May 1;29(5):1189-1194. doi: 10.1093/annonc/mdy062. Ann Oncol. 2018. PMID: 29462248 Free article. Clinical Trial.
80 results